Abstract
Radiolabeled lipiodol has been used for targeting liver cancer. We developed a lipiodol solution of (188)Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) and investigated its feasibility for the treatment of liver cancer. The lipiodol solution of (188)Re-TDD was well-retained in the lipiodol phase in vitro. After injection through the tail veins of mice, high lung-uptake was investigated which is evidence of embolizing activity. We also found high accumulation in hepatoma after injection through the hepatic arteries of hepatoma-bearing rats. In conclusion, the lipiodol solution of (188)Re-TDD is a promising agent for liver cancer therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Iodized Oil*
-
Liver / diagnostic imaging
-
Liver / metabolism
-
Liver Neoplasms / radiotherapy*
-
Liver Neoplasms, Experimental / radiotherapy*
-
Lung / metabolism
-
Mice
-
Organometallic Compounds / chemical synthesis*
-
Organometallic Compounds / pharmacokinetics
-
Organometallic Compounds / therapeutic use
-
Radioisotopes
-
Radionuclide Imaging
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / pharmacokinetics
-
Radiopharmaceuticals / therapeutic use
-
Rats
-
Rats, Sprague-Dawley
-
Rhenium
-
Solutions
-
Tissue Distribution
Substances
-
188Re 2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol
-
Organometallic Compounds
-
Radioisotopes
-
Radiopharmaceuticals
-
Solutions
-
Rhenium
-
Iodized Oil